Sorafenib and sunitinib in renal cell carcinoma

被引：52

作者：

Stein, Mark N.

Flaherty, Keith T.

机构：

[1] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, Canc Inst New Jersey, New Brunswick, NJ 08903 USA

[2] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

来源：

CLINICAL CANCER RESEARCH | 2007年 / 13卷 / 13期

关键词：

D O I：

10.1158/1078-0432.CCR-06-2844

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：3765 / 3770

页数：6

共 45 条

[11] Integrinαvβ3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis [J].

Eliceiri, BP ;

Klemke, R ;

Strömblad, S ;

Cheresh, DA .

JOURNAL OF CELL BIOLOGY, 1998, 140 (05) :1255-1263

[12] Sorafenib in advanced clear-cell renal-cell carcinoma [J].

Escudier, Bernard ;

Eisen, Tim ;

Stadler, Walter M. ;

Szczylik, Cezary ;

Oudard, Stephane ;

Siebels, Michael ;

Negrier, Sylvie ;

Chevreau, Christine ;

Solska, Ewa ;

Desai, Apurva A. ;

Rolland, Frederic ;

Demkow, Tomasz ;

Hutson, Thomas E. ;

Gore, Martin ;

Freeman, Scott ;

Schwartz, Brian ;

Shan, Minghua ;

Simantov, Ronit ;

Bukowski, Ronald M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134

[13] A small molecule-kinase interaction map for clinical kinase inhibitors [J].

Fabian, MA ;

Biggs, WH ;

Treiber, DK ;

Atteridge, CE ;

Azimioara, MD ;

Benedetti, MG ;

Carter, TA ;

Ciceri, P ;

Edeen, PT ;

Floyd, M ;

Ford, JM ;

Galvin, M ;

Gerlach, JL ;

Grotzfeld, RM ;

Herrgard, S ;

Insko, DE ;

Insko, MA ;

Lai, AG ;

Lélias, JM ;

Mehta, SA ;

Milanov, ZV ;

Velasco, AM ;

Wodicka, LM ;

Patel, HK ;

Zarrinkar, PP ;

Lockhart, DJ .

NATURE BIOTECHNOLOGY, 2005, 23 (03) :329-336

[14] Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer [J].

Faivre, S ;

Delbaldo, C ;

Vera, K ;

Robert, C ;

Lozahic, S ;

Lassau, N ;

Bello, C ;

Deprimo, S ;

Brega, A ;

Massimini, G ;

Armand, JP ;

Scigalla, P ;

Raymond, E .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) :25-35

[15] Role of Raf kinase in cancer: Therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway [J].

Gollob, Jared A. ;

Wilhelm, Scott ;

Carter, Chris ;

Kelley, Susan L. .

SEMINARS IN ONCOLOGY, 2006, 33 (04) :392-406

[16] Hypoxia inducible factor activates the transforming growth factor-α/epidermal growth factor receptor growth stimulatory pathway in VHL-/- renal cell carcinoma cells [J].

Gunaratnam, L ;

Morley, M ;

Franovic, A ;

de Paulsen, N ;

Mekhail, K ;

Parolin, DAE ;

Nakamura, E ;

Lorimer, IAJ ;

Lee, S .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (45) :44966-44974

[17] VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAP/ERK and SAPK/JNK signaling [J].

Gupta, K ;

Kshirsagar, S ;

Li, W ;

Gui, LZ ;

Ramakrishnan, S ;

Gupta, P ;

Law, PY ;

Hebbel, RP .

EXPERIMENTAL CELL RESEARCH, 1999, 247 (02) :495-504

[18] Tumor regression by targeted gene delivery to the neovasculature [J].

Hood, JD ;

Bednarski, M ;

Frausto, R ;

Guccione, S ;

Reisfeld, RA ;

Xiang, R ;

Cheresh, DA .

SCIENCE, 2002, 296 (5577) :2404-2407

[19] Role of VHL gene mutation in human cancer [J].

Kim, WY ;

Kaelin, WG .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (24) :4991-5004

[20] Design and discovery of small molecules targeting Raf-1 kinase [J].

Lowinger, TB ;

Riedl, B ;

Dumas, J ;

Smith, RA .

CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (25) :2269-2278

← 1 2 3 4 5 →